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Abstract
Recent studies suggest that in some tissues GRP receptor activation can both stimulate phospholipase C and the
adenylate cyclase pathway and that activation of the latter pathway may be important in mediating some of its
well-described growth effects. However, other studies suggest GRP-R may not be coupled to adenylate cyclase. To
investigate this possibility, in the present study we determined the coupling of the GRP receptors to each pathway in mouse,
rat, and guinea pig pancreatic acini and compared it to that in mouse Swiss 3T3 cells and human SCLC cells, all of which
possess well-characterized GRP receptors. Moreover, we tested the effect of PKC activation on the ability of GRP-related
peptides to increase cAMP accumulation in these tissues. Changes in cAMP levels were determined with or without IBMX
present, with or without forskolin, or both to amplify small increases in cAMP. In mouse, rat and guinea pig pancreatic
acini, murine Swiss 3T3 cells and human SCLC cells, GRP-related peptides caused a 600%, 500%, 250%, 300% and 60%
w3 xincrease, respectively, in H IP with 1–3 nM causing a half-maximal effect. In murine Swiss 3T3 cells, IBMX, forskolin,
and IBMX plus forskolin caused a 300%, 3500% and 10 500% increase in cAMP, respectively. GRP-related peptides and
 .VIP caused an additional 70% increase in cAMP with GRP causing a half-maximal EC increase in cAMP at 2.1"0.550
w3 xnM, which was not significantly different from the EC of 3.1"0.9 nM for increasing H IP in these cells. GRP-related50
peptides did not stimulate increases in cAMP in mouse, rat or guinea pig pancreatic acini or in SCLC cells either alone,
with IBMX or forskolin or both. However, in pancreatic acini IBMX, forskolin or both increased cAMP 3 to 8-, 10 to 500-,
and 100 to 1000-fold increase and the addition of VIP caused an additional 20-, 2-, and 3-fold increase in cAMP in the
different species. In mouse pancreatic acini with TPA alone or IBMX plus TPA, neither bombesin nor GRP increased
cAMP. Furthermore, in mouse pancreatic acini, neither TPA nor TPA plus IBMX altered basal or VIP-stimulated increases
in cAMP. In mouse Swiss 3T3 cells TPA significantly increased cAMP stimulated by Bn, GRP or VIP. These results
demonstrated that GRP receptor activation in normal tissues from three different species and a human tumoral cell line do
not result in adenylate cyclase activation, whereas in Swiss 3T3 cells it causes such activation. The results suggest that the
difference in coupling to adenylate cyclase is likely at least partially due to a difference in coupling to an adenylate cyclase
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subtype whose activation is regulated by PKC. Therefore, the possible growth effects mediated by this receptor in different
embryonic or tumoral cells through activation of adenylate cyclase are not likely to be an important intracellular pathway
for these effects in normal tissues. q 1997 Elsevier Science B.V. All rights reserved.
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1. Introduction
 .Gastrin-releasing peptide GRP is the mammalian
homologue of the amphibian tetradecapeptide
bombesin and it is thought to have a role in numerous
w xdiverse physiological and pathological processes 1 .
These include such varied roles as effects in the
central nervous system regulation of circadian
w x.rhythm, thermoregulation, regulation of satiety 1 ;
effects in the gastrointestinal tract release of numer-
w xous gastrointestinal hormones 2 , gallbladder and
w xgastrointestinal smooth muscle contraction 1 , stimu-
w x.lation of pancreatic secretion 3 ; effects on the
w ximmune system 4,5 ; and effects on development
 w x.normal lung maturation 6 . GRP is one of the most
potent neuropeptides with effects on growth of nor-
mal tissues bronchial endothelial cells, uterine stomal
w x.cells, pancreas, Swiss 3T3 cells 7–9 ; and stimula-
tion of tumor cells human small cell lung cancer
w x w x.cells 10 , breast and prostate cancers 10–12 . In
some cells, such as human cell lung cancer cells,
GRP-related peptides have an autocrine growth effect
w x10 .
Pharmacological and cloning studies demonstrate
that the actions of GRP are mediated by the GRP
 .receptor GRP-R , which is a member of the G
w xprotein-coupled superfamily 3,13 . In all tissues ex-
amined activation of the GRP receptor results in
 .activation of phospholipase C PLC , breakdown of
phosphoinositides and mobilization of intracellular
w xcalcium 1,3,7 . Whether activation of the GRP-R
also causes activation of adenylate cyclase is unclear.
Recent studies in rat GH pituitary cells, rat GH C3 4 1
w xpituitary tumor cells 14,15 and murine Swiss 3T3
w xcells 16–18 , demonstrate that activation of the
GRP-R also increases cAMP levels. Furthermore,
cAMP increases in response to GRP-R activation in
some cells may have an important role in GRP-in-
w xduced mitogenesis and growth 17,18 . However,
other studies in the same species in which it has been
shown also to activate adenylate cyclase, and in
different species, suggest that the GRP-R may not
w xalways be coupled to adenylate cyclase 19–21 . This
possible differential coupling of the GRP to adenylate
cyclase is not due to different subtypes of GRP-R
receptors because only a single GRP-R is found in
w xcloning studies 3,13 . Other possibilities include dif-
fering experimental conditions account for these dif-
ferences or that this receptor, even in the same species,
can be coupled to different intracellular signaling
pathways in different tissues.
To address the question of whether GRP receptor
activation is generally coupled to both the adenylate
cyclase cascade and the phospholipase C cascade, in
the present study we have examined whether the
activation of the GRP-R in several well-studied cell
systems in different species, as well as within differ-
ent tissues of the same species, results in increases in
activity of PLC, increases in cAMP levels, or both.
Moreover, we have examined whether activation of
PKC with phorbol esters modifies the ability of
GRP-related peptides to increase cAMP accumulation
in different tissues in the same species because recent
w xstudies 22–25 demonstrate that activation of PKC
can effect activation of adenylate cyclase in some
tissues by various receptors.
2. Materials and methods
2.1. Materials
 .Male Sprague-Dawley rats 150–200 g , male
 . guinea pigs 150–200 g and male Swiss mice 15–35
.g were obtained from the Small Animals Section
Veterinary Resources Branch of the National Insti-
tutes of Health. 125I-adenosine 3,5X-cyclic monophos-
 .phate cAMP; 2,200 Cirmmol , and cAMP anti-
serum were from New England Nuclear Boston,
.  .MA . Neuromedin B NMB , gastrin-releasing pep-
 .  .tide GRP , vasoactive intestinal peptide VIP ,
 .bombesin Bn , and secretin were from Peninsula
 .Laboratories Belmont, CA . Swiss 3T3 cells were a
gift from Dr. John Taylor Biomeasure Inc., Hopkin-
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. w 3 x  .ton, MA . Myo- 2- H inositol 16–20 Cirmmol was
 .from New England Nuclear Boston, MA .
Standard incubation buffer consisted of 98 mM
NaCl, 6 mM KCl, 25 mM Hepes, 5 mM pyruvate, 5
 .mM fumarate, 5 mM glutamate, 0.2% wrv soybean
trypsin inhibitor, 11.5 mM glucose, 0.5 mM CaCl , 12
 .  .mM MgCl , 0.2% wrv BSA, 1% vrv essential2
 .vitamin mixture and 1% vrv amino acid mixture.
The incubation solution was equilibrated with 100%
O , and all incubations were carried out with O in2 2
the gas phase.
2.2. Tissue preparation
Dispersed acini from rat pancreas, guinea pig pan-
creas, and mouse pancreas were prepared using the
w xmodifications described previously 26 .
2.3. Maintenance of cell lines
Swiss 3T3 cells were maintained by culturing in
DMEM containing 10% fetal calf serum at 378C in a
5% CO atmosphere. NCI-H345 cells were main-2
w xtained in culture as described previously 27 .
2.4. cAMP
Pancreatic acini or mechanically disaggregated cul-
tured cells were suspended in standard incubation
solution containing 300 mM IBMX, 25 mM forskolin,
both forskolin and IBMX, or neither. In a typical
experiment basal values of cAMP without IBMX or
forskolin present were performed with the following
 6concentrations of cells: Swiss 3T3 cells 5=10
.  6 .cellsrml , NCI-H345 cells 5=10 cellsrml , rat,
guinea pig and mouse pancreatic acini acini from
one pancreas diluted in 10, 10, and 2 ml of standard
.incubation buffer . With IBMX, dilutions required for
the basal values to remain in the cAMP standard
curve were: Swiss 3T3 cells, NCI-H345 cells, mouse
pancreatic acini, and rat pancreatic acini, 5-fold;
guinea pig pancreatic acini, 7-fold. With forskolin,
the dilutions required for the basal values to remain
in the cAMP standard curve were: Swiss 3T3 cells,
30-fold; NCI-H345, 250-fold; mouse pancreatic acini,
25-fold; rat pancreatic acini, 20-fold; guinea pig pan-
creatic acini, 250-fold. With both forskolin and
IBMX, the dilutions required for the basal values to
remain in the cAMP standard curve were: Swiss 3T3
cells, 100-fold; NCI-H345, 500-fold; mouse pancre-
atic acini, 250-fold; rat pancreatic acini, 500-fold;
and guinea pig pancreatic acini, 1000-fold. Cellular
cAMP was determined by radioimmunoassay, as de-
w xscribed previously 28 . When forskolin was used,
cells were preincubated for 30 min. Cyclic AMP
results are expressed as the experimental value over
the control value which was the amount of cAMP
seen with no peptides present and without IBMX or
forskolin present. Agonist concentrations causing
 .half-maximal EC increases in cAMP were calcu-50
lated using the curve-fitting program Kaleidograph.
2.5. Measurement of inositol phosphates.
Changes in total inositol phosphates were deter-
w 3 xmined in pancreatic acini using myo- 2- H inositol
and the various cell types as described previously
w x17 . Concentrations of agonists causing half-maximal
w3 xFig. 1. Ability of GRP-related peptides to stimulate H inositol
w3 x .phosphate H IP generation in Swiss 3T3 cells. Confluent cells
w 3 xwere incubated with 100 mCirml myo- 2- H inositol for 2 h,
washed and incubated with the indicated concentration of agonist
w3 xfor 30 min. Total H IP was determined using anion exchange
chromatography, as described in METHODS. Data are expressed
as the percentage of the maximal stimulated increase obtained
using 1 mM bombesin. The control and the 1 mM bombesin
 .values ns4 were 3630"307 and 9660"740 dpm, respec-
tively. Each data point represents the mean"SEM of at least four
separate experiments. Abbreviations are the same as Table 1.
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 . w3 xEC stimulation of H IP were calculated using a50
 .curve-fitting program Kaleidograph .
2.6. Statistical analysis.
The results are presented as means"SEM of four
or more experiments. Statistical comparisons were
performed using analysis of variance with the Dun-
nett’s test for significance from control values. For
the effects of TPA, a Student’s t test was used. A P
value -0.05 was considered significant.
3. Results
To compare the ability of GRP-related peptides to
increase cAMP levels andror activate phospholipase
 . w3 xC PLC and cause increases in H IP, the effects of
various naturally occurring GRP-related peptides were
compared to that of vasoactive intestinal peptide
 .VIP , a peptide known to activate adenylate cyclase
and increase cAMP in many tissues including pancre-
w x w xatic acini 3,28 and Swiss 3T3 cells 29 and that of
carbachol, a muscarinic cholinergic receptor agonist,
known to activate PLC, but not adenylate cyclase in
w xnumerous tissues such as pancreatic acini 3 . In order
not to miss low levels of activation of adenylate
cyclase, studies were performed with or without
IBMX, a phosphodiesterase inhibitor or with
forskolin, a direct activator of adenylate cyclase which
may augment the increase in cAMP caused by vari-
ous stimulants of adenylate cyclase.
Fig. 2. Ability of GRP-related peptides to increase cAMP accu-
mulation in Swiss 3T3 cells. Confluent cells were preincubated
 .for 30 min with forskolin 25 mM and then incubated with the
indicated concentration of agonist for 1 h. cAMP was determined
as described in Section 2. Data are expressed as the increase in
cAMP caused by each peptide. The control value was 341"49
pmolr106 cells and was subtracted. Each data point represents
the mean"SEM of at least five separate experiments.
Bn and the structurally-related peptides, GRP and
w3 xNMB, stimulated an increase in H IP and in cAMP
 .levels in Swiss 3T3 cells Figs. 1 and 2, Table 1 ,
 .  .whereas VIP 1 mM and carbachol 0.1 mM caused
Table 1
Ability of VIP, carbachol and GRP-related peptides to increase cAMP accumulation in Swiss 3T3 cells
 .Secretagogue cAMP experimentalrcontrol
 .  .Alone qIBMX 0.3 mM qForskolin 25 mM qIBMX and Forskolin
aNone 1 3.0"0.1 35"6 105"2
) ) ) .VIP 10 nM 1.2"0.1 3.8"0.2 60"11 147"18
 .Carb 0.1 mM 1.0"0.1 3.1"0.2 36"2 112"6
) ) ) .Bn 1 mM 1.3"0.1 4.5"0.6 58"11 171"11
) ) ) .GRP 1 mM 1.1"0.1 4.8"1.0 61"14 160"10
) ) ) .NMB 1 mM 1.3"0.2 4.2"0.4 56"12 151"16
 6 .Cells 5=10 cellsrml were incubated for 1 h alone or with secretagogues with or without IBMX 0.3 mM, forskolin 25 mM, or both.
Cells receiving forskolin were preincubated for 30 min. cAMP is expressed as the experimental value divided by the control value. Each
data point represents the mean"SEM of at least six experiments. Abbreviations: Bnsbombesin; Carbscarbachol; IBMXs
isobutylmethylxanthine; VIPsvasoactive intestinal peptide; GRPsgastrin-releasing peptide; NMBsneuromedin B.
a Control value without IBMX, forskolin or secretagogues added was 12.3"2.2 pmolr106 cells.
)  .Significant increase over incubations containing no secretagogue added P-0.05 .
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w3 x  . no changes in H IP data not shown , and VIP 10
.  .nM but not carbachol 0.1 mM increased cAMP
 .levels Table 1 . For stimulation of increases in
w3 xH IP, GRP, Bn and NMB were equally efficacious,
with maximal concentrations of each peptide causing
 .a 3-fold increase Fig. 1 . For stimulating increases in
w3 xH IP in Swiss 3T3 cells, GRP and Bn were equipo-
 .tent EC , 3.1"0.9 nM and were 145-fold more50
 .  .potent than NMB EC , 436"76 nM Fig. 1 . For50
increasing cAMP in the presence of forskolin, GRP
and Bn were equally efficacious and equipotent
 .EC , 2.1"0.3 nM and were 750-fold more potent50
 .  .than NMB EC , 1548"176 nM Fig. 2 . The50
 .addition of the PDE inhibitor IBMX 0.3 mM in-
creased basal cAMP levels 3-fold in Swiss 3T3 cells,
 .the addition of forskolin 25 mM caused a 25-fold,
 .and both together, a 105-fold increase Table 1 .
Table 2
Ability of VIP, carbachol and GRP-related peptides to increase
w3 xcAMP and H inositol phosphate accumulation in dispersed
mouse pancreatic acini
3w x  .Secretagogue cAMP H IP dpm
 .experimentalrcontrol
None 2.8"0.2 433"67
) .VIP 10 nM 63.8"7.8 645"108
) .Carb 0.1 mM 2.5"0.7 4651"1255
) .Bn 1 nM 2.6"0.1 1500"424
) .Bn 1 mM 2.9"0.8 2365"648
) .GRP 1 nM 2.8"0.3 848"86
) .GRP 1 mM 2.6"0.1 2403"551
 .NMB 10 nM 3.0"0.2 537"29
) .NMB 10 mM 2.7"0.7 1886"366
Pancreatic acini were incubated with the various secretagogues in
standard incubation buffer containing 0.3 mM IBMX for 1 h for
w3 xcAMP determinations. For determination of H IP after loading
w 3 x  .with myo- 2- H inositol 100 mCirml in standard incubation
buffer for 2 h at 378C, and washing, pancreatic acini were
w3 xresuspended in standard phosphoinositide buffer and H IP de-
termined after incubating with various secretagogues for 30 min
w3 xat 378C. H IP and cAMP were determined as described in
Section 2. cAMP is expressed as the experimental value divided
by the control value which is the basal value of cAMP with no
IBMX present which in mouse pancreatic acini was 29"2
pmolrmg protein. Each data point represents the mean"SEM of
at least five experiments. Abbreviations: Bnsbombesin; Carbs
carbachol; IBMX s Isobutylmethylxanthine; VIP s vasoactive
intestinal peptide; GRP s gastrin-releasing peptide; NMBs
neuromedin B.
) Significant increase over incubations containing no secreta-
 .gogue added P -0.01 .
w3 xFig. 3. Ability of GRP-related peptides to stimulate H inositol
w3 x .phosphate H IP generation in dispersed mouse pancreatic
wacini. Pancreatic acini were incubated with 100 mCirml myo- 2-
3 xH inositol for 2 h, washed and incubated with the indicated
w3 xconcentration of agonist for 30 min. Total H IP was determined
using anion exchange chromatography, as described in Section 2.
Data are expressed as the percentage of the maximal stimulated
increase obtained using 1 mM bombesin. The control and the 1
 .mM bombesin values ns4 were 433"67 and 2365"648 dpm,
respectively. Each data point represents the mean"SEM of at
least four separate experiments.
Increases in cAMP by either VIP or GRP-related
peptides were best seen in the presence of forskolin
alone or forskolin with IBMX, although significant
increases were also seen with GRP and Bn in the
 .presence of IBMX Table 1 . Carbachol did not alter
cAMP levels in Swiss 3T3 cells, either alone or in the
presence of IBMX, forskolin, or with both IBMX and
 .forskolin present Table 1 .
To compare the effects of GRP receptor activation
in Swiss 3T3 cells to those in another murine tissue,
dispersed mouse pancreatic acini were used. In dis-
persed mouse pancreatic acini, carbachol and each of
 .the GRP-related peptides GRP, Bn, NMB stimu-
w3 x  .lated an increase in H IP, whereas VIP 10 nM
 .caused no increase Fig. 3, Table 2 . For increasing
w3 x  .H IP, Bn EC , 1.1"0.1 nM was 9-fold more50
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Table 3
Ability of VIP, carbachol and bombesin to increase cAMP accumulation in dispersed mouse pancreatic acini
 .Secretagogue cAMP experimentalrcontrol
 .  .Alone q IBMX 0.3 mM q Forskolin 25 mM q IBMX and Forskolin
aNone 1 2.8"0.2 15.0"2.1 123"17
) ) ) ) .VIP 10 nM 2.4"0.3 63.8"7.8 39.5"6.7 457"109
 .Carb 0.1 mM 0.9"0.1 2.5"0.2 19.4"5.3 113"20
 .Bn 1 mM 1.0"0.1 2.9"0.8 14.4"0.6 118"13
Pancreatic acini were incubated for 1 h alone or with secretagogues with or without IBMX 0.3 mM, forskolin 25 mM, or both. Pancreatic
acini receiving forskolin were preincubated for 30 min. cAMP is expressed as the experimental value divided by the control value. Each
data point represents the mean"S.E.M. of at least five experiments. Abbreviations: same as Table 1 and Table 2.
a Control value without IBMX, forskolin or secretagogues added was 29.0"1.9 pmolrmg protein.
)  .Significant increase over incubations containing no secretagogue added P-0.001 .
potent than GRP and 1400-fold more potent than
 .NMB Fig. 3 . In dispersed mouse pancreatic acini,
 .IBMX alone 0.3 mM increased cAMP 3-fold,
 .forskolin alone 25 mM 15-fold, and both together
 .  .123-fold Table 3 . The addition of VIP 10 nM with
no additions, IBMX, forskolin, or IBMX and forskolin
caused a 2.4-, 15-, 2.1-, and 3.7-fold increase in
cAMP over the stimulation in the same buffer with-
 .  .out VIP, whereas carbachol 0.1 mM or Bn 1 mM
did not stimulate increases in cAMP with IBMX,
 .forskolin, or their combination Table 3 . Similarly, 1
nM or 1 mM concentrations of none of the Bn-related
 .peptides GRP, Bn, NMB increased cAMP with
 .IBMX present Table 2 .
 .To investigate which transduction pathway s rep-
resents the usual coupling arrangement for the GRP
receptor, its ability to alter cAMP levels and PLC
activity in three other well-characterized GRP recep-
tor systems possessing only GRP receptors in three
other species were examined. In previous studies
GRP-R activation is reported to cause cAMP in-
w xcreases in rat pituitary cells 14,15 , therefore the
effects of GRP on rat pancreatic acini were studied
first. In dispersed rat pancreatic acini, IBMX alone
caused a 3-fold increase in cAMP, forskolin an 8-fold
increase and both together a 165-fold increase Table
.4 . Under identical conditions VIP caused a further
2.9-, 26-, 2- and 3-fold increase, respectively Table
.  . 4 , whereas neither carbachol 0.1 mM nor Bn 1
.  .mM altered cAMP Table 4 . Similarly, neither lower
 .concentrations of Bn 1 nM nor 1 nM or 1 mM GRP
 .or NMB increased cAMP data not shown . The lack
of response was not due to the dispersed rat pancre-
atic acini not being responsive to GRP-related pep-
tides because sufficiently high concentrations of GRP,
w3 xBn, and NMB each caused a 5-fold increase in H IP
in these cells, whereas carbachol caused a 15-fold
 . w3 xincrease data not shown . For increasing H IP, Bn
was the most potent, causing a half-maximal increase
at 1.1"0.1 nM, whereas GRP was 10-fold less
Table 4
233Ability of VIP, carbachol and bombesin to increase cAMP accumulation in dispersed rat pancreatic acini
 .Secretagogue cAMP experimentalrcontrol
 .  .Alone IBMX 0.3 mM q Forskolin 25 mM qIBMX and Forskolin
aNone 1 2.6"0.5 8.7"1.1 165"10
) ) ) ) .VIP 10 nM 2.9"0.2 67.7"5.3 18.7"1.8 474"83
 .Carb 0.1 mM 0.8"0.1 2.7"0.4 9.6"0.3 160"1
 .Bn 1 mM 0.9"0.1 2.7"0.5 8.5"1.7 176"26
Pancreatic acini were incubated for 1 h alone or with secretagogues with or without IBMX 0.3 mM, forskolin 25 mM, or both. Pancreatic
acini receiving forskolin were preincubated for 30 min. cAMP is expressed as the experimental value divided by the control value. Each
data point represents the mean"SEM of at least five experiments. Abbreviations: same as Table 1 and Table 2.a Control value without
IBMX, forskolin or secretagogues added was 18.8"1.6 pmolrmg protein.) Significant increase over incubations containing no
 .secretagogue added P-0.001 .
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Table 5
Ability of VIP, carbachol and bombesin to increase cAMP accumulation in dispersed guinea pig pancreatic acini
 .Secretagogue cAMP experimentalrcontrol
 .  .Alone qIBMX 0.3 mM qForskolin 25 mM qIBMX and Forskolin
aNone 1 7.8"0.6 510"81 1204"211
) ) ) ) .VIP 10 nM 1.8"0.2 106"9 1085"171 2200"189
 .Carb 0.1 mM 1.1"0.1 7.5"0.4 493"69 1008"148
 .Bn 1 mM 1.1"0.1 7.4"0.7 533"80 1118"119
Pancreatic acini were incubated for 1 h alone or with secretagogues with or without IBMX 0.3 mM, forskolin 25 mM, or both. Pancreatic
acini receiving forskolin were preincubated for 30 min. cAMP is expressed as the experimental value divided by the control value. Each
data point represents the mean"SEM of at least five experiments. Abbreviations: same as Table 1 and Table 2.a Control value without
IBMX, forskolin or secretagogues added was 12.2"2.3 pmolrmg protein.) Significant increase over incubations containing no
 .secretagogue added P-0.001 .
potent and NMB 500-fold less potent at increasing
w3 x  .H IP data not shown .
With dispersed guinea pig pancreatic acini, IBMX
alone caused an 8-fold increase in cAMP, forskolin a
510-fold increase and both together a 1200-fold in-
 .crease Table 5 . The addition of 10 nM VIP caused a
14-, 2- and 2-fold additional increase, respectively,
and without IBMX or forskolin caused a 2-fold in-
 . crease Table 5 . In contrast, neither carbachol 0.1
.mM nor 1 mM Bn alter cAMP either alone, with
IBMX or forskolin alone, or with IBMX and forskolin
 .in combination Table 5 . Furthermore, neither a
 .lower concentration of Bn 1 nM nor 1 nM or 1 mM
GRP or NMB increased cAMP in guinea pig pancre-
 .atic acini data not shown . In contrast to the results
with cAMP, carbachol and each of the GRP-related
w3 x peptides increased the generation of H IP data not
. w3 xshown . Bn caused a half-maximal increase in H IP
at 0.93"0.24 nM and was 10-fold more potent than
GRP and 1500-fold more potent than NMB EC -50
.  .1520"447 nM data not shown .
In the human SCLC cell line, NCI-H345, IBMX
caused a 4-fold, forskolin a 650-fold, and both to-
 .gether a 1000-fold increase in cAMP Table 6 . The
addition of VIP caused an additional 300%, 40%, and
50% increase in cAMP, whereas neither GRP-related
 .peptides GRP, Bn, NMB nor carbachol altered
cAMP either alone, with IBMX, with forskolin, or
 .with IBMX and forskolin Table 6 . However, carba-
chol, GRP, Bn, and NMB each caused a significant
 . w3 xincrease p -0.05 in H IP in this human small
wcell lung cancer cell line i.e., control 148"11 dpm;
 .  .carb 0.1 mM 248"11; Bn 1 mM 210"10; GRP
 .  . x1 mM 237"28; NMB 1 mM 206"10 dpm .
w xIn a previous study in murine Swiss 3T3 cells 25 ,
the extent of activation of PKC was reported to effect
the increase in cAMP seen with GRP-related pep-
 .tides. Either with IBMX present Table 7 or forskolin
Table 6
Ability of VIP and GRP-related peptides to increase cAMP accumulation in NCI-H345 cells
 .Secretagogue cAMP experimentalrcontrol
 .  .Alone q IBMX 0.3 mM q Forskolin 25 mM q IBMX and Forskolin
aNone 1 3.6"0.1 654"41 979"90
) ) ) ) .VIP 10 nM 1.9"1.1 14.1"2.3 938"74 1496"174
 .Bn 1 mM 1.1"0.1 3.9"0.2 693"50 1047"117
 .GRP 1 mM 1.0"0.1 3.9"0.2 724"56 935"59
 .NMB 1 mM 0.9"0.1 3.7"0.2 664"61 932"113
 6 .Cells 5=10 cellsrml were incubated for 1 h at 378C with the different secretagogues with or without IBMX, forskolin, or both. Cells
receiving forskolin were preincubated for 30 min at 378C. cAMP is expressed as the experimental value divided by the control value.
Each data point represents the mean"SEM of at least five experiments. Abbreviations: same as Table 1 and Table 2.a Control value
without IBMX, forskolin or secretagogues added was 10.4"0.3 pmolr106 cells.) Significant increase over incubations containing no
 .secretagogue added P-0.001 .
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Table 7
Effect of the phorbol ester TPA on the ability of VIP, carbachol
or GRP-related peptides to increase cAMP in mouse pancreatic
acini or mouse Swiss 3T3 cells
6 .Secretagogue cAMP pmolr10 cells
Mouse Swiss Mouse pancreatic
3T3 Cells acini
Alone qTPA Alone qTPA
None 37"1 48"1 82"7 82"7
) .VIP 10 nM 46"3 70"7 1826"205 1695"272
 .Carb 0.1 mM 38"3 51"2 73"5 78"8
) .Bn 1 mM 56"7 119"6 85"23 80"8
) .GRP 1 mM 60"12 127"20 74"3 80"14
Mouse Swiss 3T3 cells and mouse pancreatic acini were incu-
 .bated with the various secretagogues and IBMX 0.3 mM , with
 .or without TPA 0.3 mM , for 1 h at 378C. cAMP was deter-
mined as described in Methods. Each data point represents the
mean"SEM of at least three experiments. Abbreviations: TPA
s12-O-tetradodecanoyl phorbol 13-acetate; remaining abbrevia-
tions are the same as Table 1 and Table 2.
)  .Significant increase over incubations without TPA P -0.05 .
 .present data not shown , in murine Swiss 3T3 cells
the activation of PKC by the addition of 0.3 mM
TPA augmented the increase in cAMP caused by
VIP, GRP or Bn. Similar studies in dispersed mouse
pancreatic acini demonstrated that neither TPA alone
 .  .  .0.3 mM nor TPA 0.3 mM and IBMX 0.3 mM
 .Table 7 either altered VIP-stimulated increases in
cAMP or effected the lack of stimulation of cAMP
 .by Bn or GRP 1 mM .
4. Discussion
GRP receptor activation is reported to activate
w xPLC in all tissues from all species examined 1,7 .
w xRecently a number of results 16,18 , however, sug-
gest that at least in some tissues the GRP-R may
 . w xresemble receptors for histamine H 30 , PACAP2
w x w x w x31 , endothelin 32 , and glucagon 33 in being able
to activate both adenylyl cyclase and PLC pathways.
w xSpecifically, in rat pituitary cell lines 14,15 and in
w xSwiss 3T3 cells 16 the addition of GRP-related
peptides causes an increase in cAMP accumulation.
The increase in cAMP in Swiss 3T3 cells caused by
GRP is diminished by PKC down-regulation and by
treatment with indomethacin which suggest that acti-
vation of PKC and the release of E type prosta-
glandins provide two distinct pathways involved in
the enhancement of cAMP accumulation by GRP in
w x w xthis cell 25 . Furthermore, recent studies 17,18,34
suggest that the increase in cAMP caused by GRP
may be important in GRP-induced activation of
protooncogenes and mitogenesis. Specifically, in
Swiss 3T3 cells transfected with a plasmid vector
 .encoding for a mutated protein kinase A PKA
regulatory subunit or a low K cAMP phosphodi-m
esterase, it was demonstrated that GRP receptor-
stimulated increases in cAMP and activation of PKA
are essential in mediating the mitogenesis caused by
w x w xGRP 18 . Furthermore, Benya et al., 17 described
that mouse GRP-R stably transfected into BALBr3T3
cells was fully coupled to G proteins and receptor
activation caused PLC activation in an identical fash-
ion to the native receptor on Swiss 3T3 cells. How-
ever, activation of the transfected GRP-R in
BALBr3T3 cells did not increase cAMP accumula-
tion, did not increase c-fos or cause growth. That
these processes were coupled was suggested in this
w xstudy 17 by the demonstration that H-89, a protein-
kinase A inhibitor, markedly attenuated the ability of
GRP to stimulate increases in c-fos in Swiss 3T3
cells, suggesting that the cAMP pathway was impor-
tant in mediating GRP-stimulated c-fos increases and
w xgrowth. Lastly, a recent study 34 demonstrates two
GRP receptor antagonists decrease cyclic AMP and
inhibit the growth of SW-1900 human pancreatic
adenocarcinoma, suggesting cAMP production by
GRP receptor activation may have an important en-
dogenous growth effect in these cells.
Whereas the above studies suggest GRP-R stimu-
lated increases in cAMP and PLC activity may be
important in mediating its effects in some tissues
w x14,16,17 , some results suggest this may not always
w xbe the case. Firstly, a recent study 17 demonstrates
that activation of the murine Swiss 3T3 cell GRP-R
stably transfected into BALB 3T3, which are closely
related to Swiss 3T3 cells, does not cause increases in
w xcAMP. In another study 35 , after transfection of the
murine Swiss 3T3 cell GRP receptor into frog
melanophores, GRP-related peptides cause no change
in cAMP accumulation. In both of these transfection
studies the GRP-R was fully coupled to PLC, there-
fore the failure to increase cAMP raises the possibil-
ity that the stimulation of adenylate cyclase by GRP-R
activation might be a cell specific feature. In addi-
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w xtion, a recent study 36 reports that activation by
GRP-related peptides of the human GRP receptor,
stably transfected into mouse BALB 3T3 cells, did
not increase cAMP accumulation even though it re-
sults in )20-fold in PLC activity. Data from native
GRP receptors in humans is limited, so that at present
it is not possible to determine whether this lack of
coupling to adenylate cyclase is cell specific. Sec-
ondly, in older studies, GRP or BN has been reported
not to increase cAMP in some tissues including
w xhamster HIT-T15 insulinoma cells 37 , and some rat
w xand guinea pig tissues 20,21,38 .
A number of explanations could account for the
variation in the ability of GRP-R activation to stimu-
late adenylate cyclase activity in different studies.
The first possibility is that differences in methodolo-
gies or experimental conditions could influence the
results. In various studies, sensitive methods to detect
w xcAMP were not always used 21 . In many tissues
under certain experimental conditions the ability to
detect increases in cAMP can be influenced by the
presence of phosphodiesterase inhibitors or by the
state of adenylate cyclase activation which in some
cases can be altered by PKC activation or by direct
w xactivators such as forskolin 16,17 . A second possi-
bility is that there may exist different GRP receptor
subtypes coupled to different intracellular pathways
in these different tissues. This has been described for
w xH histamine receptor subtype 30 , various prosta-2
w xglandin receptor subtypes 39 and various vaso-
w xpressin receptor subtypes 40 . Thirdly, the same
GRP receptor subtype could be present on different
tissues but it might be coupling in the same tissue to
different intracellular pathways in different species.
For example, recent studies demonstrated that the
CCK-related peptide, CCK-JMV 180, can function as
a receptor antagonist in guinea pig pancreatic acini, a
partial agonist at both affinity states in mouse pancre-
atic acini and a partial agonist of the high affinity
w xstate only in rat pancreatic acini 41,42 . Whereas
these results demonstrate different coupling of the
 .same receptor i.e., the CCK receptor with thisA
agonist in different species, the mediators remain
unclear. Finally, it could be suggested that the same
GRP receptor subtype can be coupled either to differ-
ent intracellular pathways in different tissues in the
same species or to different intracellular pathways in
normal cells and either tumoral or embryonic cells.
Even though this latter possibility has not been
shown with peptide hormone receptors, our results
and results previously reported by other authors sug-
gest that last proposal is the most likely explanation
for the variable effects of GRP-R activation on
adenylate cyclase in different tissues. In our study we
w xconfirm previous reports 16–18 that GRP-related
peptides stimulate increases in both cAMP and PLC
activity in mouse Swiss 3T3 cells. These results are
similar to those recently described for GRP-R activa-
w xtion in rat pituitary cell lines 14,15 . In contrast, in
our study in mouse, rat or guinea pig pancreatic acini
and human SCLC cells, GRP-R activation stimulated
increases only in PLC activity. The difference in our
study in the ability to stimulate increases in cAMP in
these various tissues was not due to a differences in
experimental conditions as suggested in the first pos-
sibility above. The experimental procedures in the
present work were the same in all tissues to avoid
differences in methodologies or experimental condi-
tions that might account for the different results in
the different tissues. A sensitive radioimmunoassay
was used to detect small changes in cAMP accumula-
tion in response to the different GRP-related peptides,
and changes in cAMP were measured either alone,
with the phosphodiesterase inhibitor IBMX or with
the direct adenylate cyclase activator, forskolin or
both. Using these conditions we could detect basal
cAMP levels in all cells and these basal levels were
in the middle of the cAMP standard curve so that
small changes could be easily detected. Furthermore,
with the addition of IBMX, forskolin or both in-
creases in cAMP greater than 100-fold occurred in all
tissues, so that if the addition of GRP-related peptides
caused increases in cAMP, the effect would be ampli-
fied and easily detected. The failure to detect in-
creases in cAMP in most tissues was not due to either
the fact the tissues were unresponsive or there was
poor coupling of the GRP-R to transduction path-
ways. In each tissue examined, VIP, which interacts
with high affinity with VIP receptors which are cou-
w xpled to adenylate cyclase 3 , increased cAMP and its
efficacy was amplified in the presence of a phospho-
diesterase inhibitor. These results demonstrate that
the lack of increase in cAMP in the different tissues
by GRP-R activation was not due to poor coupling of
receptors to adenylate cyclase. Furthermore, in each
cell system activation of the GRP-R resulted in in-
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creases in PLC activity demonstrating that GRP-R
coupling to intracellular mediators was not generally
impaired.
Recent evidence suggest that it unlikely that differ-
ent subtypes of GRP-R are present in different tissues
accounting for this variable coupling of the GRP-R to
adenylate cyclase found in the present study and
reported in other cells in the literature. Four subtypes
of receptors for bombesin-related peptides have been
 . w xdescribed, a GRP-preferring GRP-R 3,13 , a neu-
 . w xromedin B-preferring NM B-R 3,13 , a
w 13x  . w xPhe bombesin-preferring subtype BB 43 and a4
subtype that interacts with an unknown bombesin-re-
lated peptide and has a very low affinity for GRP
 . w xBRS-3, bombesin-related subtype 3 44 . In mam-
mals evidence suggest only 3 subtypes exist GRP-R,
. w xNMB-R and BRS-3 44 . In SCLC cells these 3
w xsubtypes are present 44 , however in Swiss 3T3 cells
and pancreatic acini cells which were used in the
w xpresent study, only GRP-R are found 3 . Further-
w xmore, recent studies 36,45 show that the NMB-R
activation does not increase cAMP suggesting that
the variable presence of the receptor subtype could
not be an explanation for the varying ability of GRP
to increase cAMP in different tissues.
In regard to the third possibility, it is unlike that
the difference in the ability of GRP-R activation to
increase cAMP accumulation in various tissues and
species is due to the fact that in a given tissue the
GRP-R is coupled to adenylate cyclase in one species
and not in another. In the present study in neither rat,
mouse nor guinea pig pancreatic acini was the GRP-R
coupled to adenylate cyclase. These results provide
no support for the proposal of differential coupling in
the same tissue in different species.
Our results coupled with previous studies
w x14,17,21 support the fourth possibility for the vari-
able cAMP response to GRP-R activation which is
that the GRP-R is either coupled to different intra-
cellular pathways in different cells in the same species
or to different intracellular pathways in normal cells
and either tumoral or embryonic cells. In our study in
two different murine tissues which possess GRP-R’s
which are structurally identical, Swiss 3T3 cells and
pancreatic acini demonstrated different coupling to
adenylate cyclase. Similarly, in rat pancreatic acini
w xand in rat GH and GH C 14,15,21 pituitary tumor3 4 1
cells there is a difference in coupling. Lastly, the
human SCLC cell line demonstrated no coupling of
the GRP receptor to adenylate cyclase activation;
however, a recent study provides such evidence in
human SW-1000 pancreatic adenocarcinoma cells
w x34 . Two possible explanations for these differences
might be whether the GRP-R is coupled to a
calcium-sensitive adenylate cyclase or not in a given
tissue, or whether the GRP-R is coupled to other
pathways as activation of phospholipase A . Recent2
studies demonstrate a modulation of adenylate cy-
clase activity by calcium and PKC in several tissues
and evidence has been provided that calcium-sensi-
tive adenylate cyclase may provide coupling between
the calcium and the cAMP signal transduction system
w x22,23 . Six mammalian adenylate cyclase cDNA’s
w xrecently have been cloned 22,46 . Although these
enzymes share structural characteristics, emerging ev-
idence indicates that each may have distinct tissue
distribution and regulatory properties. For example,
type I and III adenylate cyclases are stimulated by
2q w xCa in the presence of calmodulin 22 and are
neural specific, the types V and VI enzyme are
inhibited by Ca2q, independently of calmodulin and
are widely distributed among all tissues, whereas
2q w xtypes II and IV are insensitive to Ca 46 , but type
w xII is stimulated by PKC activation 22 , and each has
a wide tissue distribution. Overall, activation of the
PLC pathway has the potential to exert a major
influence on cAMP synthesis, given that only one of
the current six full length adenylate cyclases are not
responsive to either Ca2q or PKC. Previous studies
w x  .22 show that phorbol esters PDB and PMA , which
activate PKC, can profoundly increase cAMP synthe-
sis by type II adenylate cyclase. In mouse Swiss 3T3
cells the addition of TPA in the present study and the
addition of phorbol 12,13-dibutyrate in the presence
w xof forskolin or cholera toxin in another study 25
caused marked and rapid accumulation of cAMP. In
Swiss 3T3 cells this cAMP stimulatory effect has
been shown to be prevented by down-regulation of
w xPKC 16 . Our data show that in mouse pancreatic
acini with the phorbol ester TPA alone or with
IBMX, neither Bn nor GRP increased cAMP. Fur-
thermore, in pancreatic acini, neither TPA nor TPA
plus IBMX altered basal or VIP-stimulated increases
in cAMP. However, in mouse Swiss 3T3 cells, under
identical conditions, TPA significantly increased
cAMP stimulated by Bn or GRP. This effect could be
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due to a different isoform of PKC in these cells, a
different form of adenylate cyclase or some other
signaling molecule coupling adenylate cyclase to PKC
activation. Because our results demonstrated that
GRP-related peptides activates PLC in a similar man-
ner in Swiss 3T3 cells and in pancreatic acinar and
SCLC cells, it is unlikely that a failure to activate
PKC could explain the loss of adenylate activation in
mouse, rat and guinea pig pancreatic acini and SCLC
cells after GRP-R stimulation. GRP-R activation in
Swiss 3T3 cells has been proposed to activate PLA 2
w x7,16 leading to the generation of prostaglandins
which are proposed to be partially responsible for the
cAMP increase in these cells. It therefore is possible
that GRP-R might be differentially coupled to this
pathway in various embryonic or tumor cells, ex-
plaining its ability to differentially activate adenylate
cyclase.
In conclusion, this study demonstrates that GRP-R
activation in normal tissues from three different
species and a human tumoral cell line does not result
in adenylate cyclase activation, however in Swiss
3T3 cells it is coupled to adenylate cyclase. In con-
trast to results from the Swiss 3T3 cell, which has
been the model system for investigating the cellular
basis of action of GRP, our results show GRP recep-
tor activation does not usually increase cAMP. There-
fore, the possible growth effects mediated by this
receptor in different embryonic or tumoral tissues
through activation of this pathway are not likely to be
functional in these normal tissues. The ability of
GRP-R activation to increase cAMP in some embry-
onic or tumor tissues, but not in others, in the same
or in different species could partially be related to the
differential coupling of the GRP-R to an adenylate
cyclase subtype that is activated by PKC, a different
isoform of PKC, or to activation of the PLA path-2
way in different tissues. It remains unclear whether
the GRP-R can be differentially coupled to different
pathways in different normal cells of the same species.
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